4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Sickle Cell Disease by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 510 ongoing clinical trials involving Sickle Cell Disease
Of the 510 trials,152 trials are in Phase III
Furthermore, 149 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Sickle Cell Disease by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Sickle Cell Disease, a hematological disorder. The largest number of ongoing clinical trials for Sickle Cell Disease is conducted in North America. Europe and Middle East and Africa are among some of the other prominent regions engaged in Sickle Cell Disease-related drug trials.

Global Blood Therapeutics Inc: The leading ongoing Sickle Cell Disease related clinical trial sponsor

Global Blood Therapeutics Inc is the top sponsor for Sickle Cell Disease-related ongoing clinical trials.

Novartis AG, National Heart Lung and Blood Institute, CIncinnati Children's Hospital Medical Center, University of Pittsburgh, and Emory University are among other notable clinical trial sponsors involved in Sickle Cell Disease. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Sickle Cell Disease

Voxelotor (Oxbryta), Crizanlizumab-TMCA (Adakveo, Chylotrez), and Glutamine (Endari) are among the key marketed drugs involving Sickle Cell Disease.

Voxelotor (Oxbryta) is a hematologic agent. Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization. Nonclinical studies suggest that voxelotor may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity. It is formulated as film coated tablet for oral route of administration. Voxelotor is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. Voxelotor was first approved in 2019 and is marketed in the US by Global Blood Therapeutics Inc.

Crizanlizumab-TMCA (Adakveo, Chylotrez) is a monoclonal antibody, produced by using recombinant DNA technology in chinese hamster ovary (CHO) cells. Crizanlizumab-TMCA functions via P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) Inhibitor mechanism of action. It is formulated as solution and concentrate solution for intravenous route of administration. Adakveo is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Crizanlizumab-TMCA was first approved in 2019 and is marketed globally including the US, the UK, France, and Germany by Novartis AG.